Eli Lilly shares surged more than 6% to a fresh all-time high, while Johnson & Johnson rose 3.32% to $253.005, pushing its market capitalization to $609 billion. The dual record highs show strong momentum in the pharmaceutical sector as investors rotate into large-cap healthcare names.
Eli Lilly shares surged 6% to an all-time high, and Johnson & Johnson rose 3.32% to a record $253.005, pushing its market cap to $609 billion.
The gains extended a rally in healthcare stocks, with the sector outperforming broader markets this month as investors sought defensive positions. Large-cap pharma has benefited from steady demand for established drug portfolios and clear pipeline catalysts.
Eli Lilly's advance builds on a year of gains driven by its diabetes and weight-loss drugs Mounjaro and Zepbound, which have become two of the best-selling treatments globally. Johnson & Johnson's climb pushed its valuation above $600 billion for the first time, reflecting confidence in its pharmaceutical division and medical device business.
The dual records highlight the gap between large-cap pharma and smaller biotech names, many of which have declined this year as investors favor companies with proven revenue streams. The sector's strength also reflects broader market rotation into defensive stocks as uncertainty over interest rates persists.
The rally shows institutional capital continues to favor large-cap pharma with diversified revenue bases and clear growth catalysts. Investors will watch second-quarter earnings in July for updates on drug sales trends and pipeline progress.
This article is for informational purposes only and does not constitute investment advice.
